Replies to post #32402 on Marker Therapeutics Inc (MRKR)

[attilathehunt]

It all comes down to the reputation of the management team.

They can't even get the quarter right for when to expect results...Just shows incompetence...And thus we sit with the hope that results will overcome sloppy and mismanagement!

[Phantom Lord]

I'm not going to be able to address all of your concerns and I also share your frustration. I've said previously that Marker's issue is they don't have enough new data. They made all these manufacturing adjustments and process changes but have yet to get any real data from it. I know the new data is coming but that still takes time. I get that these process improvements were necessary for them to dial in and they hopefully help long term but it put them in a bad position short term by delaying their one relevant trial.

I know absolutely nothing about DICE but the market seemed to react to their data. Doesn't matter that it was PI they still had data to support their efforts. Upon release the SP is up ~90%. As a comparison I would look to what happened with MRKR (TPIV) when the merger was first announced. While Marker had already released PI data this merger announcement was the first time the broader market could invest in it. Upon that merger announcement SP went from ~$3 to ~$10. That's ~233% increase. Since that point MRKR hasn't really released much new data other than the new focus on MRD positivity. They can sit in their fancy new facility tweaking their process all they want but until they get it into trials and get meaningful data it means nothing.

I know you are pointing to DICE because of the recent price movement but there really isn't a fair comparison between them and MRKR. The psoriasis market was ~$27B this year and expected to rise to ~$51B by 2030 (SOURCE) while the AML market was ~$1B this year and expected to rise to ~$2.5B in 2030 (SOURCE). That's a major difference. Emotionally, you shouldn't find many people who think the need for a psoriasis treatment outweighs the need for an AML treatment but the reality is the market for psoriasis is 20x the AML market so DICE can currently support a larger market cap than Marker based on the relatively minimal data they each have.